Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
J Occup Environ Med ; 64(3): e172-e182, 2022 Mar 01.
Article in English | MEDLINE | ID: mdl-35244092

ABSTRACT

OBJECTIVE: Maintaining healthful, safe, and productive work environments for workers in correctional settings is a matter of deep consequence to the workers themselves, the institutions they serve, the incarcerated individuals with whom they share space, and inevitably, to our wider community. We hypothesized that an examination of the academic literature would reveal opportunities for an improved approach to research in these settings. METHODS: We performed a scoping literature review using search terms related to the occupational and environmental health of workers in correctional environments, limited to studies performed in the United States. RESULTS: A total of 942 studies underwent title and abstract screening, 342 underwent full-text review, and 147 underwent data extraction by a single reviewer. The results revealed a body of literature that tends strongly toward analyses of stress and burnout of correctional staff, largely based on self-reported data from cross-sectional surveys. Those studies related to physical health were predominantly represented by topics of infectious disease. There were few or no studies examining exposures or outcomes related to diagnosable mental health conditions, musculoskeletal injury, environmental hazards, medical or mental health staff, immigration detention settings, or regarding incarcerated workers. There were very few studies that were experimental, longitudinal, or based on objective data. DISCUSSION: The National Institute for Occupational Safety and Health (NIOSH) has promulgated a research strategy for correctional officers that should guide future research for all workers in correctional settings, but realization of these goals will rely upon multidisciplinary collaboration, specific grants to engage researchers, and an improved understanding of the barriers inherent to correctional research, all while maintaining rigorous protection for incarcerated persons as an especially vulnerable population.


Subject(s)
Burnout, Professional , Mental Disorders , Cross-Sectional Studies , Humans , Mental Health , Prisons
2.
J Occup Environ Med ; 63(10): e737-e744, 2021 Oct 01.
Article in English | MEDLINE | ID: mdl-34597285

ABSTRACT

High ambient temperatures and strenuous physical activity put workers at risk for a variety of heat-related illnesses and injuries. Through primary prevention, secondary prevention, and treatment, OEM health providers can protect workers from the adverse effects of heat. This statement by the American College of Occupational and Environmental Medicine provides guidance for OEM providers who serve workers and employers in industries where heat exposure occurs.


Subject(s)
Heat Stress Disorders , Occupational Diseases , Occupational Exposure , Occupational Medicine , Heat Stress Disorders/epidemiology , Heat Stress Disorders/prevention & control , Hot Temperature , Humans , Occupational Diseases/epidemiology , Occupational Diseases/etiology , Occupational Diseases/prevention & control , United States
3.
Gastroenterology ; 159(1): 139-147, 2020 07.
Article in English | MEDLINE | ID: mdl-32224129

ABSTRACT

BACKGROUND & AIMS: We investigated the effects of inducing deep remission in patients with early Crohn's disease (CD). METHODS: We collected follow-up data from 122 patients (mean age, 31.2 ± 11.3 y) with early, moderate to severe CD (median duration, 0.2 years; interquartile range, 0.1-0.5) who participated in the Effect of Tight Control Management on CD (CALM) study, at 31 sites, representing 50% of the original CALM patient population. Fifty percent of patients (n = 61) were randomly assigned to a tight control strategy (increased therapy based on fecal level of calprotectin, serum level of C-reactive protein, and symptoms), and 50% were assigned to conventional management. We categorized patients as those who were vs were not in deep remission (CD endoscopic index of severity scores below 4, with no deep ulcerations or steroid treatment, for 8 or more weeks) at the end of the follow-up period (median, 3.02 years; range, 0.05-6.26 years). The primary outcome was a composite of major adverse outcomes that indicate CD progression during the follow-up period: new internal fistulas or abscesses, strictures, perianal fistulas or abscesses, or hospitalization or surgery for CD. Kaplan-Meier and penalized Cox regression with bootstrapping were used to compare composite rates between patients who achieved or did not achieve remission at the end of the follow-up period. RESULTS: Major adverse outcomes were reported for 34 patients (27.9%) during the follow-up period. Significantly fewer patients in deep remission at the end of the CALM study had major adverse outcomes during the follow-up period (P = .01). When we adjusted for potential confounders, deep remission (adjusted hazard ratio, 0.19; 95% confidence interval, 0.07-0.31) was significantly associated with a lower risk of major adverse outcome. CONCLUSIONS: In an analysis of follow-up data from the CALM study, we associated induction of deep remission in early, moderate to severe CD with decreased risk of disease progression over a median time of 3 years, regardless of tight control or conventional management strategy.


Subject(s)
Anti-Inflammatory Agents/administration & dosage , Crohn Disease/drug therapy , Adalimumab/administration & dosage , Adalimumab/adverse effects , Adult , Anti-Inflammatory Agents/adverse effects , Azathioprine/administration & dosage , Azathioprine/adverse effects , Crohn Disease/diagnosis , Crohn Disease/immunology , Crohn Disease/pathology , Disease Progression , Drug Therapy, Combination/adverse effects , Drug Therapy, Combination/methods , Female , Follow-Up Studies , Hospitalization/statistics & numerical data , Humans , Male , Prednisone/administration & dosage , Prednisone/adverse effects , Remission Induction/methods , Retrospective Studies , Severity of Illness Index , Time Factors , Treatment Outcome , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/immunology , Young Adult
4.
Inflamm Bowel Dis ; 26(2): 304-313, 2020 01 06.
Article in English | MEDLINE | ID: mdl-31644790

ABSTRACT

BACKGROUND: The Crohn's Disease Activity Index (CDAI) has been criticized for being weakly correlated with bowel inflammation. We assessed correlation between Simple Endoscopic Score for Crohn's Disease (SES-CD) and individual CDAI items stratified by disease location to better understand this relationship. METHODS: We pooled patient-level data from 3 placebo-controlled Crohn's disease (CD) trials that tested adalimumab, upadacitinib, and risankizumab. Disease location was defined as ileum only, colon only, or ileocolonic based upon colonoscopy at study entry. Pearson correlation coefficients and linear regression assessed correlations between items of the CDAI and SES-CD. RESULTS: A total of 353 patients were included (20.7% ileal, 30.6% colonic, 48.7% ileocolonic disease). Crohn's Disease Activity Index and SES-CD scores were moderately correlated (R = 0.33; P < 0.001). Among CDAI items, the strongest correlations with SES-CD were seen with very soft or liquid stool frequency (SF) and patient-reported outcome 2 (PRO2; which includes SF and abdominal pain score; both R = 0.36; P < 0.001); these correlations were numerically stronger in colonic disease (SF: R = 0.46; P < 0.001; PRO2: R = 0.44; P < 0.001) than in ileal disease (SF: R = 0.14; P = 0.23; PRO2: R = 0.21; P = 0.07), although a test for interaction was not significant. In adjusted linear regression models, the proportion of mucosa that was inflamed and the proportion of mucosa with ulceration were positively correlated, whereas the presence of strictures was inversely correlated with SF. CONCLUSIONS: The SF item of the CDAI is moderately correlated with SES-CD and independently correlated with mucosal ulceration, inflammation, and strictures. Understanding why bowel inflammation as measured endoscopically does not correlate more strongly with patients' symptoms could help develop scales that link CD pathology to patient experience.


Subject(s)
Abdominal Pain/diagnosis , Anti-Inflammatory Agents/therapeutic use , Constipation/diagnosis , Crohn Disease/drug therapy , Diarrhea/diagnosis , Endoscopy, Gastrointestinal/methods , Severity of Illness Index , Abdominal Pain/chemically induced , Adult , Clinical Trials as Topic , Constipation/chemically induced , Crohn Disease/pathology , Diarrhea/chemically induced , Drug Monitoring , Endpoint Determination/standards , Female , Follow-Up Studies , Humans , Intestinal Mucosa/drug effects , Male , Prognosis , Research Design , Wound Healing/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...